HF Sinclair swings to $648M profit as refining margins stabilize
HF Sinclair (NYSE:DINO) reported a significant financial turnaround for the first quarter of 2026, posting net income of $648 million, or $3.56 per diluted share.
HF Sinclair (NYSE:DINO) reported a significant financial turnaround for the first quarter of 2026, posting net income of $648 million, or $3.56 per diluted share.
OneMain Holdings (NYSE:OMF) reported solid financial growth for the first quarter of 2026, posting net income of $226 million, up from $213 million in the prior-year period.
Aon (NYSE:AON) delivered a robust start to 2026, reporting total revenue of $5.03 billion for the first quarter, a 6% increase compared to the prior-year period.
LyondellBasell (NYSE:LYB) reported a return to profitability for the first quarter of 2026, posting net income of $125 million, or $0.38 per diluted share.
Ares Management (NYSE:ARES) reported its financial results for the first quarter ended March 31, 2026, demonstrating continued growth in its core management business.
Genius Sports (NYSE:GENI) has finalized its acquisition of Legend, a prominent digital sports and gaming media network.
Proto Labs (NYSE:PRLB) reported record-breaking financial results for the first quarter of 2026, headlined by a more than 120% increase in GAAP net income.
The Estée Lauder Companies (NYSE:EL) reported a 5% increase in net sales to $3.7 billion for the third quarter ended March 31, 2026, as the company’s strategic "Profit Recovery and Growth Plan" (PRGP) began to deliver tangible bottom-line results.
Linde (NASDAQ:LIN) reported a strong start to 2026, with first-quarter net income rising 11% to $1.86 billion.
LyondellBasell (NYSE:LYB) reached a pivotal milestone in its European strategic assessment today, May 1, 2026, with the successful completion of the sale of select European olefins and polyolefins assets to AEQUITA.
Portland General Electric Company (NYSE:POR) reported first-quarter 2026 financial results that reflected the dual impact of a historically mild winter and a rapidly expanding industrial base.
The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has recommended the approval of AstraZeneca’s (NYSE:AZN) Truqap (capivasertib) for patients with a particularly aggressive form of prostate cancer.